Thank you for exploring the ViroPharma story. One of our primary priorities is to communicate effectively with you, our current and potential shareholders. You have many options to consider for your investment dollars, so we appreciate your time and attention.

ViroPharma is rare among biotechnology companies. We are in the enviable position of having a strong and growing balance sheet; a promising pipeline with novel drugs targeting great unmet medical needs and serious diseases; two FDA approved products that are today saving and improving lives: Vancocin® which treats two significant bacterial infections of the lower gastrointestinal tract; and Cinryze™ (C1 Esterase Inhibitor [Human]) which is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE); and an excellent and experienced team throughout our global organization.

We will continue to leverage our clinical and business development expertise and our balance sheet to expeditiously develop our current pipeline, maximize the opportunities for success of our marketed products, and bring new product opportunities into the company. Through our efforts, we believe that we will be successful in providing great value to our shareholders, our employees, the patients we seek to treat, and the physicians who treat them. At ViroPharma, we believe that the work we are doing today throughout our organization will enable us to reach our goals.

Be well –

Vincent Milano, President and Chief Executive Officer